FR2475572B1 - - Google Patents

Info

Publication number
FR2475572B1
FR2475572B1 FR8002978A FR8002978A FR2475572B1 FR 2475572 B1 FR2475572 B1 FR 2475572B1 FR 8002978 A FR8002978 A FR 8002978A FR 8002978 A FR8002978 A FR 8002978A FR 2475572 B1 FR2475572 B1 FR 2475572B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8002978A
Other languages
French (fr)
Other versions
FR2475572A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Priority to FR8002978A priority Critical patent/FR2475572A1/fr
Priority to CA000358547A priority patent/CA1158978A/en
Publication of FR2475572A1 publication Critical patent/FR2475572A1/fr
Application granted granted Critical
Publication of FR2475572B1 publication Critical patent/FR2475572B1/fr
Priority to US06/636,791 priority patent/US4522809A/en
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR8002978A 1980-02-11 1980-02-11 Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications Granted FR2475572A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR8002978A FR2475572A1 (fr) 1980-02-11 1980-02-11 Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
CA000358547A CA1158978A (en) 1980-02-11 1980-08-19 Process for obtaining lipid envelope virus subunits, notably antigens for use as vaccines, the products obtained and their applications
US06/636,791 US4522809A (en) 1980-02-11 1984-08-01 Process for obtaining lipid envelope virus sub-units, notably antigens for use as vaccines, the products obtained and their applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8002978A FR2475572A1 (fr) 1980-02-11 1980-02-11 Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications

Publications (2)

Publication Number Publication Date
FR2475572A1 FR2475572A1 (fr) 1981-08-14
FR2475572B1 true FR2475572B1 (cg-RX-API-DMAC7.html) 1982-02-19

Family

ID=9238454

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8002978A Granted FR2475572A1 (fr) 1980-02-11 1980-02-11 Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications

Country Status (3)

Country Link
US (1) US4522809A (cg-RX-API-DMAC7.html)
CA (1) CA1158978A (cg-RX-API-DMAC7.html)
FR (1) FR2475572A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2475572A1 (fr) * 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
WO1987001128A1 (en) * 1985-08-15 1987-02-26 Amgen Lysis method and buffer for extraction of hepatitis b surface antigen from yeast cells
US4790987A (en) * 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US4789545A (en) * 1986-03-31 1988-12-06 New York Blood Center, Inc. Removal of lipid soluble process chemicals from biological materials by extraction with naturally occurring oils or synthetic substitutes thereof
NZ224422A (en) * 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
EP0431129B1 (en) * 1989-06-15 1996-05-29 Rorer International (Overseas) Inc. Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
US5236840A (en) * 1990-01-18 1993-08-17 University Of Hawaii Method for growing crustacean virus in fish cells
FR2674536B1 (fr) * 1991-03-29 1994-10-21 Fondation Nale Transfusion San Procede d'inactivation de virus et composition pharmaceutique pour l'inactivation de virus.
FR2723740B1 (fr) * 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
AUPN030794A0 (en) 1994-12-22 1995-01-27 Aruba International Pty Ltd Discontinuous plasma or serum delipidation
US7407662B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US20090017069A1 (en) * 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
US7439052B2 (en) * 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
US7407663B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
MXPA03002890A (es) * 2000-10-02 2004-12-03 Glaxosmithkline Biolog Sa Preparacion de virus con envolvente dividido.
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US20060060520A1 (en) * 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
EP1412045A4 (en) * 2001-06-25 2007-05-02 Lipid Sciences Inc A SOLVENT FOR REMOVING LIPIDES FROM FLUIDS USING SYSTEMS AND METHOD
AU2002322284A1 (en) * 2001-06-25 2003-01-08 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
US20030127386A1 (en) * 2001-06-25 2003-07-10 Bomberger David C. Hollow fiber contactor systems for removal of lipids from fluids
AU2003268190B2 (en) * 2002-08-26 2008-04-03 Eli Lilly And Company Treating Alzheimers using delipidated protein particles
US7393826B2 (en) * 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US7375191B2 (en) * 2003-07-03 2008-05-20 Lipid Science, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US6960803B2 (en) * 2003-10-23 2005-11-01 Silicon Storage Technology, Inc. Landing pad for use as a contact to a conductive spacer
EP1982727A1 (en) * 2007-04-17 2008-10-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for purification of viral proteins
SG10201404101RA (en) * 2007-08-28 2014-09-26 Baxter Int Method For Producing Viral Vaccines
WO2011130119A2 (en) 2010-04-14 2011-10-20 Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
MA40920A (fr) 2014-11-07 2017-09-12 Takeda Vaccines Inc Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
CN111868232B (zh) 2017-11-22 2024-05-28 Hdl治疗公司 用于对血浆处理系统的流体回路进行灌注的系统和方法
AU2018396009A1 (en) 2017-12-28 2020-07-16 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
US11369675B2 (en) 2018-01-22 2022-06-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly protective inactivated influenza virus vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE661402A (cg-RX-API-DMAC7.html) * 1964-03-20
US3847737A (en) * 1965-03-22 1974-11-12 A Kanarek Inactivation of myxoviruses and method of preparing a vaccine therefrom
US3639578A (en) * 1970-02-18 1972-02-01 Int Minerals & Chem Corp Virus insecticide
GB1486557A (en) * 1973-10-18 1977-09-21 Flockhart & Co Process for the preparation of pyrogen-free sub-unit vaccine
FR2422720A2 (fr) * 1977-04-26 1979-11-09 Elf Aquitaine Separation et purification de proteines par chromatographie
FR2475572A1 (fr) * 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications

Also Published As

Publication number Publication date
US4522809A (en) 1985-06-11
CA1158978A (en) 1983-12-20
FR2475572A1 (fr) 1981-08-14

Similar Documents

Publication Publication Date Title
FR2473464B1 (cg-RX-API-DMAC7.html)
FR2472937B1 (cg-RX-API-DMAC7.html)
CH655632B (cg-RX-API-DMAC7.html)
FR2473963B3 (cg-RX-API-DMAC7.html)
FR2473912B1 (cg-RX-API-DMAC7.html)
FR2473132B1 (cg-RX-API-DMAC7.html)
FR2473396B1 (cg-RX-API-DMAC7.html)
DE3153250A1 (cg-RX-API-DMAC7.html)
CH663130GA3 (cg-RX-API-DMAC7.html)
FR2473371B1 (cg-RX-API-DMAC7.html)
FR2473513B1 (cg-RX-API-DMAC7.html)
FR2473373B1 (cg-RX-API-DMAC7.html)
FR2473766B1 (cg-RX-API-DMAC7.html)
CH657201B (cg-RX-API-DMAC7.html)
FR2473482B1 (cg-RX-API-DMAC7.html)
DE3050253T1 (cg-RX-API-DMAC7.html)
FR2473114B1 (cg-RX-API-DMAC7.html)
FR2473401B1 (cg-RX-API-DMAC7.html)
CH653577B (cg-RX-API-DMAC7.html)
FR2473449B1 (cg-RX-API-DMAC7.html)
DE3050629A1 (cg-RX-API-DMAC7.html)
FR2473730B1 (cg-RX-API-DMAC7.html)
FR2473217B1 (cg-RX-API-DMAC7.html)
FR2473146B1 (cg-RX-API-DMAC7.html)
DE3001906C2 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
ST Notification of lapse